TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15333605
Drug: 2 mg/2
Normalized name: risperidone 2 mg/2 mL ORAL SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/2 ml antide (n=30)
Study: 15333605
Drug: 1 mg/ml
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/ml antide (n=30)
Study: 15333605
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml antide (n=31)
Study: 15333605
Drug: 0.5 mg/0.5
Normalized name: Dilaudid, 0.5 mg/0.5 mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/0.5 ml antide (n=23)
Study: 15333605
Drug: 0.25 mg/ml
Normalized name: thiram 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/ml antide (n=30)
Study: 15333605
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml antide (considered minimal effective dose)
Study: 9813513
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion during rewarming stage of hypothermic CPB
Study: 2687645
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 50 mg i.m. every 3 weeks for 12 months + oral calcium supplement (1 g/day)
Study: 2687645
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + oral calcium supplement (1 g/day)
Study: 31778478
Drug: Kaolin treatment
Normalized name: Kaolin
DrugBank: Kaolin (DB01575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaolin treatment (T1): Immature or newly emerged adults of P. solenopsis sprayed with kaolin and fed with cotton leaf discs treated with kaolin suspension.
Study: 31778478
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water treatment (T2): Immature or newly emerged adults of P. solenopsis sprayed with distilled water and fed with cotton leaf discs treated with distilled water.
Study: 21293451
Drug: 10-mg CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg CP-945,598
Study: 21293451
Drug: 20-mg CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg CP-945,598
Study: 21293451
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lifestyle and CP-945,598
Study: 15070094
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the stomach
Study: 15070094
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the proximal small bowel
Study: 15070094
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the distal small bowel
Study: 15070094
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the ascending colon
Study: 9385564
Drug: RO 47‐0203,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 47‐0203, 30 mg/kg orally per day, two single doses
Study: 8201835
Drug: C2 (rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2 (rifampicin 40 mg/kg and 1200 mg clofazimine once)
Study: 8201835
Drug: C4 (rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C4 (rifampicin 40 mg/kg, clofazimine 100 mg, DDS 100 mg and ethionamide 500 mg once)
Study: 2838442
Drug: Neutron boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron boost irradiation (dose levels: 3.6, 4.2, 4.8, 5.2, 5.6, 6.0 Gyn gamma) along with whole brain photon irradiation (1.5 Gy per treatment, 5 days-a-week to a total dose of 45 Gy)
Study: 28322476
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment with more frequent sessions in a shorter period of time
Study: 26742305
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule (XFC) plus placebo for leflunomide (LEF)
Study: 21212367
Drug: Iopamidol (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (370 mg of iodine per milliliter, n = 63)
Study: 21212367
Drug: Iodixanol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (320 mg of iodine per milliliter, n = 67)
Study: 18078537
Drug: Risperidone (2‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2‐6 mg/day)
Study: 18078537
Drug: Haloperidol (2‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2‐40 mg/day)
Study: 17538084
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with eventual surgery if needed
Study: 28583757
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1000 mg at 6-hour intervals)
Study: 26757748
Drug: Rituximab (RTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (RTX; anti‐CD20) treatment
Study: 25178882
Drug: L. salivarius
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. salivarius WB21-containing tablets (2.0 × 10(9) colony forming units/day) for 2 weeks
Study: 25178882
Drug: L. salivarius
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. salivarius TI 2711
Study: 25178882
Drug: Ovalgen® DC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovalgen® DC (antibody against glucosyltransferase from Streptococcus mutans)
Study: 19622684
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg hydrocortisone (HCORT)
Study: 17486686
Drug: Fixed valerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed valerian hops extract combination (Ze 91019)
Study: 15114701
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day gefitinib
Study: 15114701
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day gefitinib
Study: 8151002
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no nicotine patch)
Study: 21777954
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel with 20 mg esomeprazole
Study: 21777954
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel with 150 mg ranitidine
Study: 15249570
Drug: GHRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1 mg subcutaneously twice daily)
Study: 10650325
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/d orally)
Study: 8477064
Drug: MEVP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEVP therapy (10 mg/m2 of mitoxantrone intravenously on day 1, 2 mg/m2 of vindesine intravenously on day 1, 200 mg/m2 of etoposide orally on days 1-3, and 40 mg/m2 of prednisolone orally on days 1-5, repeated every 3 weeks for up to 10 courses)
Study: 8477064
Drug: CHOP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP therapy
Study: 3513808
Drug: Control (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Conventional diuretic treatment)
Study: 21946836
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with polydextrose (PDX) and galacto-oligosaccharides (GOS) (4 g/L, 1:1 ratio)
Study: 18422771
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen patches (Fem7, 100 microg)
Study: 18422771
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone agonist therapy
Study: 8813896
Drug: Fructo-oligosaccharides 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides 5 g/d
Study: 8813896
Drug: Fructo-oligosaccharides 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides 15 g/d
Study: 8813896
Drug: Fructo-oligosaccharides (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides (both doses)
Study: 1553890
Drug: Bepridil 300
Normalized name: bepridil 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 300 mg once/day
Study: 3890587
Drug: Lofexidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine (0.4 mg orally every 6 hours for 48 hours)
Study: 25880400
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg daily for 12 weeks
Study: 26936232
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg daily for 12 weeks
Study: 22821644
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/day (Tel80)
Study: 22821644
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg + Amlodipine 5 mg (Tel40 + Aml5)
Study: 18073543
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg 20% mannitol
Study: 9273829
Drug: Alcoholic beverage
Normalized name: Alcoholic beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic beverage (0.56 g of alcohol per kg of body weight)
Study: 9273829
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (3 mL of alcohol)
Study: 3223489
Drug: Comprehensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive intervention (self-help manual, televised broadcast, weekly support meetings, supportive phone calls)
Study: 2277739
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol and systemic corticosteroids
Study: 2277739
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol and placebo
Study: 28303470
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum (2.5 g/day)
Study: 22732766
Drug: Vardenafil (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (20, 10 or 5 mg single oral doses)
Study: 16759047
Drug: Immediate enfuvirtide/optimized‐background
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate enfuvirtide/optimized‐background treatment regimen
Study: 16759047
Drug: 16‐week treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16‐week treatment interruption followed by enfuvirtide/optimized‐background treatment regimen
Study: 11699489
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HTR and ePTFE
Study: 7952370
Drug: Independent weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Independent weekly assessments
Study: 28699886
Drug: IL-1 trap
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 trap rilonacept (160 mg/week) for 12 weeks
Study: 16981859
Drug: Double-dose CEE/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose CEE/MPA (conjugated equine estrogens plus medroxyprogesterone acetate, 0.625 mg + 2.5 mg) daily
Study: 16981859
Drug: Single-dose CEE/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose CEE/MPA (0.625 mg + 2.5 mg) daily
Study: 16981859
Drug: CEE/MPA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (both doses)
Study: 11740262
Drug: G-CSF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (2 microg/kg subcutaneously once a day for 5 days)
Study: 30942028
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (once a day, 5 treatments a week for 4 weeks) at points Baihui (BL 20), Fengchi (GB 20), Pishu (BL 20), Shenshu (BL 23), Sanyinjiao (SP 6), Taixi (KI 3)
Study: 28426260
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dapagliflozin
Study: 19491213
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of a combination pill of 2.5 mg folic acid, 50 mg vitamin B6, and 1 mg vitamin B12
Study: 12739919
Drug: Nutrition counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition counseling plus a nutritional supplement (Study) for 90 days
Study: 12739919
Drug: Nutrition counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition counseling plus a nutritional supplement (Study)
Study: 8832480
Drug: Flap debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap debridement surgery + 100 mg/ml TTC solution and FFSS application
Study: 3871235
Drug: Urea treatment
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea treatment during cardiopulmonary bypass
Study: 27367745
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% four times daily
Study: 21901316
Drug: 1,017 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,017 μg salvinorin A
Study: 21901316
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg salvinorin A
Study: 17114190
Drug: MM-093 (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM-093 (21 mg weekly subcutaneous injections)
Study: 16623018
Drug: Diabetes drug
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes drug counseling by pharmacist, diabetes booklet, and special medication containers
Study: 16623018
Drug: Diabetes drug
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes drug counseling by pharmacist
Study: 16623018
Drug: All interventions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All interventions (drug counseling, booklet, containers)
Study: 9164416
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine mesylate (400 mg every 8 hours for 30 days) + Rifampin (600 mg once-daily on days 16-30)
Study: 1774018
Drug: Constant rate
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant rate iv infusion of insulin (0.034 U/kg/h) during 150 minutes
Study: 1774018
Drug: Identical infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Identical infusion of insulin with variable iv infusion of glucose to maintain euglycemia
Study: 28412602
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plus instructions in CBT
Study: 26781346
Drug: Mecapegfilgrastim 100
Normalized name: Mecapegfilgrastim
DrugBank: Mecapegfilgrastim (DB19147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecapegfilgrastim 100 μg/kg
Study: 26781346
Drug: Mecapegfilgrastim 6
Normalized name: pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mecapegfilgrastim 6 mg fixed dose
Study: 26781346
Drug: Daily rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhG-CSF
Study: 12047460
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (SV) 1000-2000 mg/day
Study: 7745334
Drug: Bismuth subgallate
Normalized name: Bismuth subgallate
DrugBank: Bismuth subgallate (DB13909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subgallate as a haemostatic agent
Study: 2039103
Drug: Rectal thiopental
Normalized name: thiopental Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal thiopental 25 mg/kg
Study: 2039103
Drug: Drug combination
Normalized name: Other anti-dementia drug combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug combination (meperidine 2 mg/kg, promethazine 1 mg/kg, chlorpromazine 1 mg/kg)
Study: 2039103
Drug: Drug combination
Normalized name: Other anti-dementia drug combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug combination
Study: 23302898
Drug: Preemptive pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive pain medication and intraoperative periarticular injections (Group I)
Study: 23302898
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving preemptive medication and injections (Group II)
Study: 22766210
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: Fentanyl 2 mg/kg + Pentothal 5 mg/kg + Vecuronium 0.1 mg/kg
Study: 22766210
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: Lidocaine 1.5 mg/kg + Fentanyl 2 mg/kg + Pentothal 5 mg/kg + Vecuronium 0.1 mg/kg
Study: 22766210
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: Lidocaine 1.5 mg/kg + Pentothal 5 mg/kg + Vecuronium 0.1 mg/kg
Study: 2347035
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (two intradermal injections on days 0, 3, and 7)
Study: 2347035
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (one intradermal and one subcutaneous injection on days 0, 3, and 7)
Study: 2347035
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (two subcutaneous injections on days 0, 3, and 7)
Study: 465440
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g guar gum in bread
Study: 465440
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g guar gum in soup
Study: 465440
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g guar gum (5 g in bread and 5 g in soup)
Study: 30632290
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg subcutaneous daily for 12 months
Study: 17874921
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy with high treatment fidelity
Study: 17874921
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy with low treatment fidelity
Study: 9758290
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trovafloxacin once daily
Study: 9758290
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trovafloxacin once daily
Study: 9758290
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg amoxicillin three times daily
Study: 9758290
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trovafloxacin
Study: 9758290
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trovafloxacin
Study: 8152575
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg/day (IV before chemotherapy and orally for 4 days)
Study: 8152575
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg x 3/day (first dose IV before chemotherapy and subsequent doses orally until the end of the fourth day after chemotherapy)
Study: 3072830
Drug: S-carboxymethylcysteine (S-CMC)
Normalized name: S-carboxymethylcysteine
DrugBank: Carbocisteine (DB04339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxymethylcysteine (S-CMC) syrup
Study: 23181712
Drug: Ingesting all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingesting all medications upon awakening
Study: 23181738
Drug: Ingesting ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting ≥1 medications at bedtime
Study: 23181712
Drug: Ingesting all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingesting all medications at bedtime
Study: 23181712
Drug: Bedtime treatment
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime treatment with ARBs
Study: 23181712
Drug: Bedtime treatment
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime treatment with calcium channel blockers
Study: 23181712
Drug: Ingesting ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting ≥1 medications at bedtime (specifically ARBs)
Study: 19932838
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg/kg (group D)
Study: 19932838
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg and midazolam 0.075 mg/kg (group DM)
Study: 9350955
Drug: Quetiapine (407
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (407 mg mean daily dose)
Study: 9350955
Drug: Chlorpromazine (384
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (384 mg mean daily dose)
Study: 8405016
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of pantoprazole (40 mg)
Study: 8405016
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of pantoprazole (40 mg)
Study: 3535986
Drug: Large dose
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dose of caffeine (15 mg X kg‐1)
Study: 3535986
Drug: Small dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dose of caffeine (10 mg X kg‐1)
Study: 28230029
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 + nedaplatin 20 mg/m2, administered on day 1 and 8 with 21 days per cycle for 3 cycles
Study: 28230029
Drug: 5-fluorouracil 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil 500 mg/m2 + cisplatin 20 mg/m2, administered on day 1-5 with 21 days per cycle for 3 cycles
Study: 20532476
Drug: Metformin (RECORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (RECORD trial)
Study: 15877299
Drug: Fenofibrate 250
Normalized name: fenofibrate 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 250 mg/d